Drug profile

The FDA adverse-event record for Dapp Vaccine From Another Manufacturer

13 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Dapp Vaccine From Another Manufacturer. See the species affected, top reactions, and outcomes below.

13
adverse-event reports
15.4%
death-coded share
Dog
most-reported species
6
Lethargy (see also Central nervous system depression in Neurological) - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
2
Deaths Reported
15.4%
Death Rate

Active Ingredients

Dapp Vaccine From Another Manufacturer

Administration Routes

Subcutaneous

Species Affected

Dog 13

Most Affected Breeds

Doberman Pinscher 2
Crossbred Canine/dog 1
Retriever - Golden 1
Chihuahua 1
Spaniel - King Charles Cavalier 1
Terrier - Bull - American Pit 1
Newfoundland 1
Mountain Dog - Bernese 1
Terrier - Boston 1
Terrier (unspecified) 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 6
Vomiting 5
Hypersensitivity reaction 3
Facial swelling (see also Skin) 2
Hives (see also Skin) 2
Elevated alanine aminotransferase (ALT) 2
Gait abnormality 2
Excessive thirst 2
Seizure NOS 2
Death 2
Neurological disorder NOS 2
Diarrhoea 2

Outcome Breakdown

Ongoing
7 (53.8%)
Recovered/Normal
4 (30.8%)
Died
2 (15.4%)

Dapp Vaccine From Another Manufacturer Adverse Event Insights

13 reports name Dapp Vaccine From Another Manufacturer; 2 recorded a death outcome (15.4% of reported events, not a population-level mortality rate). Active ingredient: Dapp Vaccine From Another Manufacturer. Administration route: Subcutaneous.

By species: Dog (13 reports). By breed: Doberman Pinscher (2), Crossbred Canine/dog (1), Retriever - Golden (1).

Leading clinical signs: Lethargy (see also Central nervous system depression in Neurological) (6), Vomiting (5), Hypersensitivity reaction (3), Facial swelling (see also Skin) (2). Outcome, 13 coded reports: Ongoing leads at 53.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.